Combination of antibody-drug conjugate and CDK9 inhibitor
AssigneesAstraZeneca UK Limited, Daiichi Sankyo Company, Limited
InventorsJerome Thomas Mettetal, II, Justin Robert Cidado, Scott Boiko
Life of this patent
Estimating the term…
Abstract
A pharmaceutical product for administration of an anti HER2 antibody-drug conjugate in combination with a CDK9 inhibitor is provided. The anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the antibody-drug conjugate and the CDK9 inhibitor are administered in combination to a subject: Formula (I):
Claims22
A pharmaceutical product comprising an anti-HER2 antibody-drug conjugate and AZD4573, which is represented by the following formula:
- or a pharmaceutically acceptable salt thereof for administration in combination, wherein the anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula:
- wherein A represents the connecting position to an antibody, is conjugated to an anti-HER2 antibody via a thioether bond and wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 consisting of an amino acid sequence represented by SEQ ID NO:
- 3, CDRH2 consisting of an amino acid sequence represented by SEQ ID NO:
- 4 and CDRH3 consisting of an amino acid sequence represented by SEQ ID NO:
- 5, and a light chain comprising CDRL1 consisting of an amino acid sequence represented by SEQ ID NO:
- 6, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 1 to 3 of SEQ ID NO:
- 7 and CDRL3 consisting of an amino acid sequence represented by SEQ ID NO:
- 8.
A method of treating cancer comprising administering to a subject in need thereof a combination of an anti-HER2 antibody-drug conjugate and AZD4573, which is represented by the following formula:
- or a pharmaceutically acceptable salt thereof,
- wherein the anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula:
- wherein A represents the connecting position to an antibody, is conjugated to an anti-HER2 antibody via a thioether bond and wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 consisting of an amino acid sequence represented by SEQ ID NO:
- 3, CDRH2 consisting of an amino acid sequence represented by SEQ ID NO:
- 4 and CDRH3 consisting of an amino acid sequence represented by SEQ ID NO:
- 5, and a light chain comprising CDRL1 consisting of an amino acid sequence represented by SEQ ID NO:
- 6, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 1 to 3 of SEQ ID NO:
- 7 and CDRL3 consisting of an amino acid sequence represented by SEQ ID NO:
- 8.
Dependencies are inferred from the claim text.